9 products found
Novavax Products
-
Covid 19
We have successfully produced NVX-CoV2373, a vaccine candidate that is designed to provide protection against COVID-19. Engineered from the genetic sequence of COVID-19, we used our recombinant nanoparticle technology to generate antigen derived from the coronavirus spike protein. In combination with our proprietary Matrix-M™ adjuvant, NVX-CoV2373 has demonstrated in preclinical studies that it binds efficiently with human receptors targeted by the virus, a critical aspect for effective vaccine protection.
-
NanoFlu - Seasonal Influenza
In March 2020, we announced positive top-line results from our Phase 3 clinical trial of our nanoparticle seasonal quadrivalent influenza vaccine candidate, including our proprietary Matrix-M™ adjuvant (NanoFlu™). The trial was a randomized, observer-blinded, active-controlled trial in approximately 2,652 healthy older adults (aged 65 years and older) across 19 clinical sites in the United States. The trial evaluated the immunogenicity and ...
-
ResVax - Model RSV F - Aluminum Adjuvanted Vaccine
ResVax is our aluminum-adjuvanted RSV F vaccine for infants via maternal immunization. RSV is the most common cause of lower respiratory tract infections (LRTI) and the leading viral cause of severe lower respiratory tract disease in infants and young children worldwide. In the United States, RSV is the leading cause of hospitalization of infants and, globally, is second only to malaria as a cause of death in children under 1 year of age. There are ...
-
Seasonal Influenza
In March 2020, we announced positive top-line results from our Phase 3 clinical trial of our nanoparticle seasonal quadrivalent influenza vaccine candidate, including our proprietary Matrix-M™ adjuvant (NanoFlu™).
-
Novavax - Model RSV F - Vaccine
Older adults (aged 60 years and older) are at increased risk for RSV disease due in part to immunosenescence, the age-related decline in the human immune system. RSV infection can also lead to exacerbation of underlying comorbidities such as chronic obstructive pulmonary disease, asthma, and congestive heart failure. In the United States alone, a reported RSV incidence rate of 5.5% in older adults would account for approximately 2.5 million infections per ...
-
Respiratory Syncytial Virus (RSV)
ResVax is our aluminum-adjuvanted RSV F vaccine for infants via maternal immunization. RSV is the most common cause of lower respiratory tract infections (LRTI) and the leading viral cause of severe lower respiratory tract disease in infants and young children worldwide.
-
Novavax - Model RSV F - Combination Seasonal Influenza Vaccine
With the ongoing development of our NanoFlu™ and RSV F vaccines, a strong rationale exists for developing a combination respiratory vaccine that is designed to protect susceptible populations against both diseases. Although testing is at an early stage, we believe that a combination vaccine against both seasonal influenza and RSV may be ...
-
Ebola Virus
We have developed an EBOV glycoprotein vaccine candidate (Ebola GP vaccine) expressed in insect cells, using our core recombinant baculovirus technology. In 5 separate studies, carried out in collaboration with the National Institute of Allergy and Infectious Diseases, active immunization with the Ebola GP vaccine was shown to be highly immunogenic and efficacious in preventing lethal disease in non-human primates challenged with EBOV. Our 2015 Phase 1 clinical trial demonstrated that our Ebola GP vaccine is highly immunogenic in humans, well tolerated, and, in conjunction with our proprietary Matrix-M™ adjuvant, showed marked antigen dose-sparing and induced significant increases in neutralizing antibody titers. Although not in active development, our Ebola GP vaccine is a viable development opportunity in the event of dedicated funding or a partnership arrangement.
-
Novavax - Middle East Respiratory Syndrome (MERS) Vaccine
Historically, we developed a vaccine candidate against MERS, a novel coronavirus first identified in 2012, as well as a vaccine candidate against SARS in 2005. In 2012, within weeks of obtaining the sequence of the circulating MERS strain, we successfully produced a vaccine candidate. Our MERS candidate was based on the major surface spike protein, which we had previously identified as the antigen of choice in our work with our SARS vaccine candidate. In ...
-
Novavax - Severe Acute Respiratory Syndrome (SARS) Vaccine
Historically, we developed a vaccine candidate against MERS, a novel coronavirus first identified in 2012, as well as a vaccine candidate against SARS in 2005. In 2012, within weeks of obtaining the sequence of the circulating MERS strain, we successfully produced a vaccine candidate. Our MERS candidate was based on the major surface spike protein, which we had previously identified as the antigen of choice in our work with our SARS vaccine candidate. In ...
-
Novavax - Model GP - Glycoprotein Vaccine
We have developed an EBOV glycoprotein vaccine candidate (Ebola GP vaccine) expressed in insect cells, using our core recombinant baculovirus technology. In 5 separate studies, carried out in collaboration with the National Institute of Allergy and Infectious Diseases, active immunization with the Ebola GP vaccine was shown to be highly immunogenic and efficacious in preventing lethal disease in non-human primates challenged with EBOV. Our 2015 Phase 1 ...
-
Technology
Our recombinant nanoparticle vaccine technology combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic particles that target a variety of viral pathogens.
-
Novavax - Recombinant Nanoparticle Vaccine Technology
Our recombinant nanoparticle vaccine technology combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic particles that target a variety of viral pathogens. Our recombinant vaccine engineering takes a new approach to provide robust and functional immunity, which may be more efficacious than naturally occurring immunity or traditional vaccines. Using innovative proprietary recombinant nanoparticle vaccine ...
-
Matrix - Model M - Adjuvant Technology
Novavax' saponin-based Matrix-M improves immune responses and enables vaccine dose-sparing. Matrix-M adjuvant is a valuable component of vaccine development, providing multiple immune system enhancements, a well-understood mechanism of action, and robust clinical experience where it was shown to be well tolerated in human studies to ...